Please Wait.....
Report
Global Cold Sore Treatment (for HSV 1 Virus) Market
Market Report I 2024-05-01 I 405 Pages I Data Bridge Market Research
Global cold sore treatment (for HSV 1 virus) market is expected to reach USD 1,501.88 million by 2031, from USD 927.29 million in 2023, growing at the CAGR of 6.6% in the forecast period of 2024 to 2031.
Market Segmentation
Global Cold Sore Treatment (for HSV 1 Virus) Market, By Treatment Type (Medications, Applied Products, Cold Sore Patches, and Others(Non Medicated Products)), Route Of Administration (Oral, Topical, and Others), Mode Of Purchase (Over The Counter and Prescription Drug), Strain Type (Herpes Simplex Type 1 Virus and Herpes Simplex Type 2 Virus), Drug Type (Generic and Branded), Population Type (Adults, Pediatrics, and Geriatrics), Gender (Female and Male), End User (Home Healthcare, Hospitals, Specialty Clinics, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others), By Country (U.S., Canada, and Mexico, U.K., Germany, France, Spain, Italy, Belgium, Russia, Switzerland, Netherlands, Turkey, and rest of Europe, China, Australia, Japan, India, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, and rest of Asia-Pacific, Brazil, Argentina, and rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., and rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Cold Sore Treatment (for HSV 1 Virus) Market Dynamics
Drivers
- Growing prevalence of cold sore infection
- Growing awareness about cold sore symptoms and treatment options
- Impact of generic drugs on the global cold sore treatment (for HSV 1 virus) market
Restraints
- Development of drug-resistant strains of HSV-1 and H11 viruses
- Lack of curative treatment for infection
Opportunities
- Rising advancements in treatments for cold sore infections
- Increasing adoption of telemedicine and digital health solutions
Challenges
- Increasing complexity of vaccine development
- Side effects associated with medications in treating cold sore
Market Players
The key market players for global cold sore treatment (for HSV 1 virus) market are listed below:
- Fresenius SE & Co. KGaA
- Zydus Pharmaceuticals, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Quantum Health
- GSK plc.
- Haleon Group of Companies
- Church & Dwight Co., Inc.
- Hikma Pharmaceuticals PLC
- Viatris Inc.
- Carma Labs Inc.
- URGO MEDICAL
- Apotex Inc.
- Amneal Pharmaceuticals LLC
- Blistex Inc.
- FOCUS CONSUMER HEALTHCARE
- Hetero Healthcare Limited
- Amparo medical Technologies
- Devirex AG
1 INTRODUCTION 50
1.1 OBJECTIVES OF THE STUDY 50
1.2 MARKET DEFINITION 50
1.3 OVERVIEW OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET 50
1.4 CURRENCY AND PRICING 52
1.5 LIMITATIONS 52
1.6 MARKETS COVERED 52
2 MARKET SEGMENTATION 56
2.1 MARKETS COVERED 56
2.2 GEOGRAPHICAL SCOPE 57
2.3 YEARS CONSIDERED FOR THE STUDY 58
2.4 DBMR TRIPOD DATA VALIDATION MODEL 59
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
2.6 MULTIVARIATE MODELLING 63
2.7 MARKET APPLICATION COVERAGE GRID 64
2.8 PRODUCT LIFELINE CURVE 65
2.9 DBMR MARKET POSITION GRID 66
2.10 VENDOR SHARE ANALYSIS 67
2.11 SECONDARY SOURCES 68
2.12 ASSUMPTIONS 68
3 EXECUTIVE SUMMARY 69
4 PREMIUM INSIGHTS 72
4.1 PESTEL ANALYSIS 75
4.2 PORTER'S FIVE FORCES 76
5 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: REGULATIONS 77
5.1 REGULATION IN U.S.: 77
5.2 REGULATION IN CANADA: 78
5.3 REGULATION IN SPAIN: 78
5.4 REGULATION IN U.K.: 79
5.5 REGULATION IN INDIA 80
?
6 MARKET OVERVIEW 82
6.1 DRIVERS 84
6.1.1 GROWING PREVALENCE OF COLD SORE INFECTION 84
6.1.2 GROWING AWARENESS ABOUT COLD SORE SYMPTOMS AND TREATMENT OPTIONS 84
6.1.3 IMPACT OF GENERIC DRUGS ON THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET 85
6.2 RESTRAINTS 86
6.2.1 DEVELOPMENT OF DRUG-RESISTANT STRAINS OF HSV-1 AND H11 VIRUSES 86
6.2.2 LACK OF CURATIVE TREATMENT FOR INFECTION 87
6.3 OPPORTUNITIES 88
6.3.1 RISING ADVANCEMENTS IN TREATMENTS FOR COLD SORE INFECTIONS 88
6.3.2 INCREASING ADOPTION OF TELEMEDICINE AND DIGITAL HEALTH SOLUTIONS 89
6.4 CHALLENGES 90
6.4.1 INCREASING COMPLEXITY OF VACCINE DEVELOPMENT 90
6.4.2 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS IN TREATING COLD SORE 91
7 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE 92
7.1 OVERVIEW 93
7.2 MEDICATIONS 96
7.2.1 ANTIVIRAL AGENTS 96
7.2.2 ANALGESIC AGENTS 97
7.2.3 OTHERS 97
7.3 APPLIED PRODUCTS 97
7.3.1 BRANDED 98
7.3.2 GENERICS 98
7.4 COLD SORE PATCHES 99
7.4.1 SEMI OCCLUSIVE HYDROCOLLOID PATCH 99
7.4.2 FILM FORMING PATCH 99
7.5 OTHERS (NON MEDICATED PRODUCTS) 100
8 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION 101
8.1 OVERVIEW 102
8.2 ORAL 105
8.2.1 TABLETS 105
8.2.2 CAPSULES 105
8.2.3 OTHERS 105
?
8.3 TOPICAL 106
8.3.1 CREAM 106
8.3.2 LIP BALM 106
8.3.3 OTHERS 106
8.4 OTHERS 107
9 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE 108
9.1 OVERVIEW 109
9.2 OVER THE COUNTER 112
9.3 PRESCRIPTION DRUG 112
10 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE 113
10.1 OVERVIEW 114
10.2 HERPES SIMPLEX TYPE 1 VIRUS 117
10.3 HERPES SIMPLEX TYPE 2 VIRUS 117
11 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE 118
11.1 OVERVIEW 119
11.2 GENERIC 122
11.3 BRANDED 122
12 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE 124
12.1 OVERVIEW 125
12.2 ADULTS 128
12.3 PEDIATRICS 128
12.4 GERIATRICS 129
13 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER 130
13.1 OVERVIEW 131
13.2 FEMALE 134
13.3 MALE 134
14 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER 135
14.1 OVERVIEW 136
14.2 HOME HEALTHCARE 139
14.3 HOSPITALS 139
14.4 SPECIALTY CLINICS 140
14.5 OTHERS 140
15 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL 141
15.1 OVERVIEW 142
15.2 DIRECT TENDERS 145
15.3 RETAIL SALES 145
16 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION 147
16.1 OVERVIEW 148
16.2 NORTH AMERICA 152
16.2.1 U.S. 158
16.2.2 CANADA 164
16.2.3 MEXICO 170
16.3 EUROPE 176
16.3.1 GERMANY 182
16.3.2 FRANCE 188
16.3.3 U.K. 194
16.3.4 ITALY 200
16.3.5 SPAIN 206
16.3.6 RUSSIA 212
16.3.7 SWITZERLAND 218
16.3.8 NETHERLAND 224
16.3.9 TURKEY 230
16.3.10 BELGIUM 236
16.3.11 REST OF EUROPE 242
16.4 ASIA-PACIFIC 243
16.4.1 CHINA 250
16.4.2 JAPAN 256
16.4.3 INDIA 262
16.4.4 AUSTRALIA 268
16.4.5 SOUTH KOREA 274
16.4.6 SINGAPORE 280
16.4.7 MALAYSIA 285
16.4.8 PHILIPPINES 291
16.4.9 INDONESIA 297
16.4.10 THAILAND 303
16.4.11 REST OF ASIA-PACIFIC 309
?
16.5 SOUTH AMERICA 310
16.5.1 BRAZIL 317
16.5.2 ARGENTINA 323
16.5.3 REST OF SOUTH AMERICA 329
16.6 MIDDLE EAST AND AFRICA 330
16.6.1 SOUTH AFRICA 337
16.6.2 EGYPT 344
16.6.3 SAUDI ARABIA 350
16.6.4 U.A.E. 357
17 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY LANDSCAPE 364
17.1 COMPANY SHARE ANALYSIS: GLOBAL 364
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 365
17.3 COMPANY SHARE ANALYSIS: EUROPE 366
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 367
18 SWOT ANALYSIS 368
19 COMPANY PROFILE 369
19.1 FRESENIUS SE & CO. KGAA 369
19.1.1 COMPANY SNAPSHOT 369
19.1.2 REVENUE ANALYSIS 369
19.1.3 COMPANY SHARE ANALYSIS 370
19.1.4 PRODUCT PORTFOLIO 370
19.1.5 RECENT DEVELOPMENT 370
19.2 ZYDUS PHARMACEUTICALS INC. 371
19.2.1 COMPANY SNAPSHOT 371
19.2.2 COMPANY SHARE ANALYSIS 371
19.2.3 PRODUCT PORTFOLIO 372
19.2.4 RECENT DEVELOPMENT 372
19.3 TEVA PHARMACEUTICAL INDUSTRIES LTD. 373
19.3.1 COMPANY SNAPSHOT 373
19.3.2 REVENUE ANALYSIS 373
19.3.3 COMPANY SHARE ANALYSIS 374
19.3.4 PRODUCT PORTFOLIO 374
19.3.5 RECENT DEVELOPMENT 375
?
19.4 NOVARTIS AG 376
19.4.1 COMPANY SNAPSHOT 376
19.4.2 REVENUE ANALYSIS 376
19.4.3 COMPANY SHARE ANALYSIS 377
19.4.4 PRODUCT PORTFOLIO 377
19.4.5 RECENT DEVELOPMENT 377
19.5 SUN PHARMACEUTICALS INDUSTRIES LIMITED 378
19.5.1 COMPANY SNAPSHOT 378
19.5.2 REVENUE ANALYSIS 378
19.5.3 COMPANY SHARE ANALYSIS 379
19.5.4 PRODUCT PORTFOLIO 379
19.5.5 RECENT DEVELOPMENT 379
19.6 AMNEAL PHARMACEUTICALS LLC 380
19.6.1 COMPANY SNAPSHOT 380
19.6.2 REVENUE ANALYSIS 380
19.6.3 PRODUCT PORTFOLIO 381
19.6.4 RECENT DEVELOPMENT 381
19.7 AMPARO MEDICAL TECHNOLOGIES 382
19.7.1 COMPANY SNAPSHOT 382
19.7.2 PRODUCT PORTFOLIO 382
19.7.3 RECENT DEVELOPMENT 382
19.8 APOTEX INC. 383
19.8.1 COMPANY SNAPSHOT 383
19.8.2 PRODUCT PORTFOLIO 383
19.8.3 RECENT DEVELOPMENT 383
19.9 BLISTEX INC. 384
19.9.1 COMPANY SNAPSHOT 384
19.9.2 PRODUCT PORTFOLIO 384
19.9.3 RECENT DEVELOPMENT 384
19.10 CARMA LABS INC. 385
19.10.1 COMPANY SNAPSHOT 385
19.10.2 PRODUCT PORTFOLIO 385
19.10.3 RECENT DEVELOPMENT 385
19.11 CHURCH & DWIGHT CO., INC. 386
19.11.1 COMPANY SNAPSHOT 386
19.11.2 REVENUE ANALYSIS 386
19.11.3 PRODUCT PORTFOLIO 387
19.11.4 RECENT DEVELOPMENT 387
?
19.12 DEVIREX AG 388
19.12.1 COMPANY SNAPSHOT 388
19.12.2 PRODUCT PORTFOLIO 388
19.12.3 RECENT DEVELOPMENT 388
19.13 FOCUS CONSUMER HEALTHCARE 389
19.13.1 COMPANY SNAPSHOT 389
19.13.2 PRODUCT PORTFOLIO 389
19.13.3 RECENT DEVELOPMENT 389
19.14 GSK PLC. 390
19.14.1 COMPANY SNAPSHOT 390
19.14.2 REVENUE ANALYSIS 390
19.14.3 PRODUCT PORTFOLIO 391
19.14.4 RECENT DEVELOPMENT 391
19.15 HALEON GROUP OF COMPANIES 392
19.15.1 COMPANY SNAPSHOT 392
19.15.2 REVENUE ANALYSIS 392
19.15.3 PRODUCT PORTFOLIO 393
19.15.4 RECENT DEVELOPMENT 393
19.16 HETERO HEALTH CARE LIMITED 394
19.16.1 COMPANY SNAPSHOT 394
19.16.2 PRODUCT PORTFOLIO 394
19.16.3 RECENT DEVELOPMENT 394
19.17 HIKMA PHARMACEUTICALS PLC 395
19.17.1 COMPANY SNAPSHOT 395
19.17.2 REVENUE ANALYSIS 395
19.17.3 PRODUCT PORTFOLIO 396
19.17.4 RECENT DEVELOPMENT 396
19.18 QUANTUM HEALTH 397
19.18.1 COMPANY SNAPSHOT 397
19.18.2 PRODUCT PORTFOLIO 397
19.18.3 RECENT DEVELOPMENT 398
19.19 URGO MEDICAL 399
19.19.1 COMPANY SNAPSHOT 399
19.19.2 PRODUCT PORTFOLIO 399
19.19.3 RECENT DEVELOPMENT 399
19.20 VIATRIS INC. 400
19.20.1 COMPANY SNAPSHOT 400
19.20.2 REVENUE ANALYSIS 400
19.20.3 PRODUCT PORTFOLIO 401
19.20.4 RECENT DEVELOPMENT 401
20 QUESTIONNAIRE 402
21 RELATED REPORTS 405
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security